Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Feb 22 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-0.90 Insider Own3.62% Shs Outstand33.41M Perf Week1.02%
Market Cap17.21M Forward P/E- EPS next Y-0.80 Insider Trans23.72% Shs Float32.20M Perf Month12.79%
Income-26.27M PEG- EPS next Q-0.21 Inst Own15.51% Short Float0.68% Perf Quarter-4.79%
Sales0.00M P/S- EPS this Y13.12% Inst Trans0.31% Short Ratio1.35 Perf Half Y-8.04%
Book/sh1.18 P/B0.44 EPS next Y9.12% ROA-50.09% Short Interest0.22M Perf Year-59.45%
Cash/sh0.74 P/C0.70 EPS next 5Y- ROE-56.16% 52W Range0.34 - 1.65 Perf YTD-40.00%
Dividend Est.- P/FCF- EPS past 5Y20.36% ROI-73.72% 52W High-68.79% Beta1.94
Dividend TTM- Quick Ratio7.10 Sales past 5Y0.00% Gross Margin- 52W Low52.50% ATR (14)0.05
Dividend Ex-Date- Current Ratio7.10 EPS Y/Y TTM-2.76% Oper. Margin0.00% RSI (14)44.68 Volatility7.58% 8.47%
Employees19 Debt/Eq0.02 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price7.33
Option/ShortNo / Yes LT Debt/Eq0.01 EPS Q/Q37.43% Payout- Rel Volume0.33 Prev Close0.50
Sales Surprise- EPS Surprise14.91% Sales Q/Q- EarningsNov 13 BMO Avg Volume162.77K Price0.51
SMA201.99% SMA50-14.93% SMA200-10.23% Trades Volume53,627 Change2.75%
Date Action Analyst Rating Change Price Target Change
Jul-18-22Resumed Oppenheimer Outperform $14
Jan-24-24 08:50AM
Dec-20-23 09:16PM
Dec-11-23 08:50AM
Nov-14-23 01:46PM
08:05AM Loading…
Nov-13-23 08:05AM
Nov-07-23 08:45AM
Nov-06-23 08:35AM
Oct-24-23 07:45AM
Oct-18-23 10:00AM
Oct-11-23 09:05AM
Oct-02-23 08:40AM
Sep-22-23 07:58AM
Sep-21-23 08:50AM
08:40AM Loading…
Sep-18-23 08:40AM
Sep-14-23 08:35AM
Sep-05-23 08:35AM
Aug-12-23 12:16AM
Aug-11-23 06:45AM
Aug-10-23 04:05PM
Aug-07-23 08:40AM
Aug-03-23 08:45AM
Jul-13-23 08:40AM
Jul-06-23 08:45AM
Jun-13-23 08:35AM
May-30-23 09:05AM
May-12-23 11:15AM
May-11-23 08:04AM
04:05PM Loading…
May-10-23 04:05PM
May-04-23 08:35AM
May-02-23 08:35AM
Apr-24-23 09:55AM
Apr-18-23 05:33PM
Mar-27-23 12:00PM
Mar-24-23 05:33AM
Mar-23-23 07:10AM
Mar-22-23 04:20PM
Mar-21-23 08:50AM
Mar-15-23 08:30AM
Mar-13-23 08:35AM
Mar-09-23 08:35AM
Mar-01-23 08:45AM
Feb-13-23 11:30AM
Jan-11-23 01:00PM
Jan-05-23 08:45AM
Dec-21-22 08:25AM
Dec-19-22 09:15AM
Dec-15-22 01:09PM
Dec-07-22 08:45AM
Nov-14-22 05:23PM
Nov-10-22 04:05PM
Nov-07-22 09:05AM
Oct-14-22 08:40AM
Sep-27-22 01:01PM
Sep-23-22 09:11AM
Sep-08-22 08:45AM
Sep-07-22 08:35AM
Sep-06-22 08:45AM
Aug-19-22 08:40AM
Aug-15-22 08:35AM
Jul-28-22 08:35AM
Jul-11-22 10:22AM
Jul-08-22 08:35AM
Jun-16-22 08:35AM
May-26-22 08:35AM
May-19-22 08:05AM
May-12-22 08:35AM
May-10-22 08:35AM
May-05-22 08:15AM
May-04-22 08:15AM
Apr-21-22 08:47AM
Apr-14-22 08:05AM
Apr-11-22 07:05AM
Apr-08-22 01:05PM
Mar-25-22 07:05AM
Mar-23-22 08:05AM
Mar-11-22 08:05AM
Mar-01-22 08:35AM
Feb-14-22 02:10PM
Feb-01-22 09:11AM
Jan-20-22 08:40AM
Jan-18-22 08:05AM
Jan-12-22 10:35AM
Jan-07-22 08:30AM
Dec-27-21 08:05AM
Dec-01-21 08:35AM
Nov-12-21 08:05AM
Nov-11-21 08:05AM
Nov-04-21 02:30PM
Oct-20-21 05:46PM
Oct-19-21 09:05AM
Moleculin Biotech, Inc. is a clinical stage pharmaceutical company. It engages in the business of growing a pipeline including phase 2 clinical programs for hard-to-treat cancers and viruses. The company was founded by Walter V. Klemp, Donald H. Picker, and Waldemar Priebe on July 28, 2015 and is headquartered in Houston, TX.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
KLEMP WALTER VCEO and PresidentDec 26Buy0.69188,404129,999680,880Dec 27 07:31 AM
Foster Jonathan P.Chief Financial OfficerDec 26Buy0.6928,98620,00080,556Dec 27 07:32 AM
George Robert E.DirectorDec 26Buy0.6914,49310,00014,660Dec 27 07:31 AM